within Pharmacolibrary.Drugs.ATC.V;

model V08CA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.027000000000000003,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.00020999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Gadoteridol is a non-ionic, macrocyclic gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) to enhance the visibility of internal body structures. It is approved for use in adults and children to improve diagnostic accuracy in central nervous system, head, neck, and body imaging.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single intravenous injection.</p><h4>References</h4><ol><li><p>Naganawa, S, et al., &amp; Ikeda, M (2014). Time course for measuring endolymphatic size in healthy volunteers following intravenous administration of gadoteridol. <i>Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine</i> 13(2) 73–80. DOI:<a href=&quot;https://doi.org/10.2463/mrms.2013-0080&quot;>10.2463/mrms.2013-0080</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24769637/&quot;>https://pubmed.ncbi.nlm.nih.gov/24769637</a></p></li><li><p>Naganawa, S, et al., &amp; Sakurai, Y (2014). Serial scans in healthy volunteers following intravenous administration of gadoteridol: time course of contrast enhancement in various cranial fluid spaces. <i>Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine</i> 13(1) 7–13. DOI:<a href=&quot;https://doi.org/10.2463/mrms.2013-0056&quot;>10.2463/mrms.2013-0056</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24492743/&quot;>https://pubmed.ncbi.nlm.nih.gov/24492743</a></p></li><li><p>Shellock, FG, &amp; Kanal, E (1999). Safety of magnetic resonance imaging contrast agents. <i>Journal of magnetic resonance imaging : JMRI</i> 10(3) 477–484. DOI:<a href=&quot;https://doi.org/10.1002/(sici)1522-2586(199909)10:3&lt;477::aid-jmri33&gt;3.0.co;2-e&quot;>10.1002/(sici)1522-2586(199909)10:3&lt;477::aid-jmri33&gt;3.0.co;2-e</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10508312/&quot;>https://pubmed.ncbi.nlm.nih.gov/10508312</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V08CA04;
